FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BELANOFF JOSEPH K						2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]									ck all app Direc	ctor	2	X 10% (Owner	
(Last) (First) (Middle) C/O CORCEPT THERAPEUTICS 275 MIDDLEFIELD ROAD, SUITE A						3. Date of Earliest Transaction (Month/Day/Year) 05/12/2005									X Officer (give title below) Other (specify below) Chief Executive Officer					
(Street) MENLO PARK CA 94025					- 4. I1 - -	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)		(Sta		Zip)	Davis												1			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day			ction	ion 2A. Deemed Execution Date,		ed Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A)		ed (A) o	r	5. Amount o Securities Beneficially Owned Follo		Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
										Code	v	Amount	(A) oi (D)	Pric	e	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)
Common Stock 05/12				05/12/	2005				S ⁽¹⁾		2,500	D	\$	\$4.1 2,341		11,695	95 D			
Common Stock															300,000			I	Custodian for minor son ⁽²⁾	
Common Stock															300	0,000		I	Custodian for a minor daughter ⁽²⁾	
Common Stock 05/13/20				2005				S ⁽¹⁾		3,400	D	\$4.	1879	2,338,295		D				
Common Stock 05/16/20				2005	005			S ⁽¹⁾		1,100	D	\$4.	2045	2,337,195		D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	ecurity ecurity nstr. 3) Conversion or Exercise Price of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year)		4. Transa Code (8)	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y		isable and	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

Explanation of Responses:

- 1. The sale on this Form 4 was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 15, 2004.
- 2. The Reporting Person is the custodian for minor children and disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.

Remarks:

s/s Fred Kurland, CFO of **Corcept Therapeutics** Incorporated attorney-in-fact

05/16/2005

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.